Clinical Trial Update: Effect of Deferasirox on Endocrine Complications in Subjects With Transfusion Dependent Thalassemia [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluating whether deferasirox affects endocrine complications in patients with transfusion-dependent thalassemia was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Transfusion-dependent Thalassemia

Drugs mentioned

• Deferasirox (Deferasirox)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Thalassemia (Transfusion Delendent) | Phase 4 | Status: WITHDRAWN